196 related articles for article (PubMed ID: 16813654)
1. Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study.
Hall P; Ploner A; Bjöhle J; Huang F; Lin CY; Liu ET; Miller LD; Nordgren H; Pawitan Y; Shaw P; Skoog L; Smeds J; Wedrén S; Ohd J; Bergh J
BMC Med; 2006 Jun; 4():16. PubMed ID: 16813654
[TBL] [Abstract][Full Text] [Related]
2. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
Ritte R; Lukanova A; Berrino F; Dossus L; Tjønneland A; Olsen A; Overvad TF; Overvad K; Clavel-Chapelon F; Fournier A; Fagherazzi G; Rohrmann S; Teucher B; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Panico S; Tumino R; Vineis P; Quirós JR; Buckland G; Sánchez MJ; Amiano P; Chirlaque MD; Ardanaz E; Sund M; Lenner P; Bueno-de-Mesquita B; van Gils CH; Peeters PH; Krum-Hansen S; Gram IT; Lund E; Khaw KT; Wareham N; Allen NE; Key TJ; Romieu I; Rinaldi S; Siddiq A; Cox D; Riboli E; Kaaks R
Breast Cancer Res; 2012 May; 14(3):R76. PubMed ID: 22583394
[TBL] [Abstract][Full Text] [Related]
3. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
5. Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort.
Chapman JA; Nielsen TO; Ellis MJ; Bernard P; Chia S; Gelmon KA; Pritchard KI; Le Maitre A; Goss PE; Leung S; Shepherd LE; Bramwell VH
Breast Cancer Res; 2013; 15(4):R71. PubMed ID: 23972025
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Dew JE; Wren BG; Eden JA
Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer.
Yariv O; Mutai R; Rotem O; Tsoref D; Korzets Y; Moore A; Shochat T; Yerushalmi R; Goldvaser H
Oncology; 2021; 99(11):713-721. PubMed ID: 34515186
[TBL] [Abstract][Full Text] [Related]
8. Type and duration of exogenous hormone use affects breast cancer histology.
Kumar AS; Cureton E; Shim V; Sakata T; Moore DH; Benz CC; Esserman LJ; Hwang ES
Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262
[TBL] [Abstract][Full Text] [Related]
9. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
10. Reduced incidence of distant metastases and lower mortality in 1072 patients with breast cancer with a history of hormone replacement therapy.
Schuetz F; Diel IJ; Pueschel M; von Holst T; Solomayer EF; Lange S; Sinn P; Bastert G; Sohn C
Am J Obstet Gynecol; 2007 Apr; 196(4):342.e1-9. PubMed ID: 17403414
[TBL] [Abstract][Full Text] [Related]
11. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
Liu D; Zhou K
Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
[TBL] [Abstract][Full Text] [Related]
12. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast.
Hofseth LJ; Raafat AM; Osuch JR; Pathak DR; Slomski CA; Haslam SZ
J Clin Endocrinol Metab; 1999 Dec; 84(12):4559-65. PubMed ID: 10599719
[TBL] [Abstract][Full Text] [Related]
13. Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer.
Bonnier P; Bessenay F; Sasco AJ; Beedassy B; Lejeune C; Romain S; Charpin C; Piana L; Martin PM
Int J Cancer; 1998 Jun; 79(3):278-82. PubMed ID: 9645351
[TBL] [Abstract][Full Text] [Related]
14. [Hormone replacement therapy, proliferation in the breast and risk of carcinoma].
Strnad P; Rob L; Zuntová A; Moravcová Z; Chod J; Halaska M
Ceska Gynekol; 2002 Nov; 67(6):337-43. PubMed ID: 12661372
[TBL] [Abstract][Full Text] [Related]
15. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Diamandis EP; Yu H; Look MP; Meijer-van Gelder ME; van Putten WL; Klijn JG
Br J Cancer; 1999 Feb; 79(5-6):888-94. PubMed ID: 10070886
[TBL] [Abstract][Full Text] [Related]
16. [The estrogen receptor/progesterone receptor quotient as an index of the transcriptional activity of estrogen receptors in breast cancer].
Navarro MA; Díez Gibert O; Fernández-Montolí ME; Rosel P; Bonnin MR
Med Clin (Barc); 1995 May; 104(18):681-2. PubMed ID: 7769876
[TBL] [Abstract][Full Text] [Related]
17. Hormone replacement therapy and high S phase in breast cancer.
Cobleigh MA; Norlock FE; Oleske DM; Starr A
JAMA; 1999 Apr; 281(16):1528-30. PubMed ID: 10227323
[TBL] [Abstract][Full Text] [Related]
18. Low biologic aggressiveness in breast cancer in women using hormone replacement therapy.
Holli K; Isola J; Cuzick J
J Clin Oncol; 1998 Sep; 16(9):3115-20. PubMed ID: 9738583
[TBL] [Abstract][Full Text] [Related]
19. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women.
Talley LI; Grizzle WE; Waterbor JW; Brown D; Weiss H; Frost AR
Int J Cancer; 2002 Mar; 98(1):118-27. PubMed ID: 11857395
[TBL] [Abstract][Full Text] [Related]
20. An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to HRT.
McGurgan P; Taylor LJ; Duffy SR; O'Donovan PJ
Maturitas; 2006 Mar; 53(4):454-61. PubMed ID: 16169691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
